https://orcid.org/0000-0003-1825-8547
References
- Oughton JB, Poad H, Twiddy M, et al. BRAVO study group. Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): aprotocol for a randomised controlled feasibility study. BMJ Open. 2017;7(8):e017913.
- Gårdmark T, Bladström A, Malmström PU, Members of The Swedish National Bladder Cancer Registry, et al. Members Of The Swedish National Bladder Cancer Registry. Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001. Scand J Urol Nephrol. 2006;40(4):276–282.
- Häggström C, Liedberg F, Hagberg O, et al. Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe). BMJ Open. 2017;7(9):e016606.
- Bellera CA, MacGrogan G, Debled M, et al. Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer. BMC Med Res Methodol. 2010;10:20.
- Häggström C, Garmo H, de Luna X, et al. Survival after radiotherapy versus radical cystectomy for primary muscle-invasive bladder cancer: a Swedish nationwide population-based cohort study. Cancer Med. 2019;8(5):2196–2204.
- Boef A, Souverein P, Vandenbroucke J, et al. Instrumental variable analysis as a complementary analysis in studies of adverse effects: venous thromboembolism and second-generation versus third-generation oral contraceptives. Pharmacoepidemiol Drug Saf. 2016;25(3):317–324.
- Davies N, Davey Smith G, Windmeijer F, et al. COX-2 selective nonsteroidal anti-inflammatory drugs and risk of gastrointestinal tract complications and myocardial infarction: an instrumental variable analysis. Epidemiology. 2013;24(3):352–362.
- Jerlström T, Chen R, Liedberg F, et al. No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study. World J Urol. 2020;38(2):381–388.
- Gershman B, Boorjian SA, Hautmann RE. Management of T1 urothelial carcinoma of the bladder: what do we know and what do we need to know? Bladder Cancer. 2015;2(1):1–14.
- Patschan O, Holmäng S, Hosseini A, et al. Second-look resection for primary stage T1 bladder cancer: a population-based study. Scand J Urol. 2017; 51(4):301–307.
- Hemdan T, Johansson R, Jahnson S, Members of the Urothelial Cancer Group of the Nordic Association of Urology, et al. Members of the Urothelial Cancer Group of the Nordic Association of Urology. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer. J Urol. 2014;191(5):1244–1249.
- Hautmann RE, Abol-Enein H, Davidsson T, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012, et al. International consultation on urologic disease-European Association of Urology Consultation on bladder cancer 2012: ICUD-EAU International Consultation on Bladder Cancer 2012: urinary diversion. Eur Urol. 2013;63(1):67–80.
- Fedeli U, Paoli AD, Corti MC, et al. Perioperative mortality and long-term survival after radical cystectomy: a population-based study in a Southern European country on 4,389 patients. Urol Int. 2020;104(7–8):559–566.
- Chalasani V, Kassouf W, Chin J, et al. Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. Can Urol Assoc J. 2011;5(2):83–87.
- Malmström PU, Rintala E, Wahlqvist R, et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol. 1996;155(6):1903–1906.